Afficher la notice abrégée

dc.contributor.authorStanden, O.D.
dc.date.accessioned2019-03-16T14:23:19Z
dc.date.accessioned2019-10-04T00:37:05Z
dc.date.available2019-03-16T14:23:19Z
dc.date.available2019-10-04T00:37:05Z
dc.date.issued1977-04
dc.identifier.citationStanden, O.D., (1977). Pre-Clinical Development of Drugs. Medical Journal of Zambia Volume 11 (2).en
dc.identifier.urihttps://library.adhl.africa/handle/123456789/11377
dc.descriptionThe purpose of this paper is to present a brief outline of the essential requirements in the post research phase of drug development.en
dc.description.abstractThe purpose of this paper is to present a brief outline of the essential requirements in the postresearch phase of drug development. At present evolution of new drugs, is largely a responsibility of the pharmaceutical industry and deployment of resources in Research and Development is inevitably linked to the profit-motive. Without this, the resources and, possibly the practical incentive, would not be readily available to support further endeavour. The dilemma arises when, as at the present time, moral and humanitarian considerations of drug development for specific purposes conflict with the monetary basis of viability of the industry.en
dc.description.sponsorshipOffice of Global AIDS/US Department of State.en
dc.language.isoenen
dc.publisherMedical Journal of Zambiaen
dc.relation.ispartofseriesVolume;11(2)
dc.subjectClinical Medicineen
dc.titlePre-Clinical Development of Drugsen
dc.typeArticleen


Fichier(s) constituant ce document

FichiersTailleFormatVue
MJZ;VOL11;2;APR-MAY1977_ Drugs.pdf3.193Moapplication/pdfVoir/Ouvrir

Ce document figure dans la(les) collection(s) suivante(s)

Afficher la notice abrégée